Preclinical Models of Visceral Sarcomas

被引:1
作者
Costa, Alice [1 ]
Gozzellino, Livia [2 ]
Nannini, Margherita [2 ,3 ]
Astolfi, Annalisa [2 ]
Pantaleo, Maria Abbondanza [2 ,3 ]
Pasquinelli, Gianandrea [2 ,4 ]
机构
[1] IRCCS Azienda Osped Univ Bologna, I-40138 Bologna, Italy
[2] Univ Bologna, Dept Med & Surg Sci DIMEC, I-40138 Bologna, Italy
[3] IRCCS Azienda Osped Univ Bologna, Div Oncol, I-40138 Bologna, Italy
[4] IRCCS Azienda Osped Univ Bologna, Div Pathol, I-40138 Bologna, Italy
关键词
soft tissue sarcomas; preclinical models; cancer-derived cells; patient-derived xenografts; genome-engineered mouse models; GASTROINTESTINAL STROMAL TUMORS; SOFT-TISSUE SARCOMAS; FACTOR VEGF OVEREXPRESSION; TYROSINE KINASE INHIBITOR; XENOGRAFT MODELS; MOUSE MODEL; CELL-LINES; CANCER; IMATINIB; GROWTH;
D O I
10.3390/biom13111624
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Visceral sarcomas are a rare malignant subgroup of soft tissue sarcomas (STSs). STSs, accounting for 1% of all adult tumors, are derived from mesenchymal tissues and exhibit a wide heterogeneity. Their rarity and the high number of histotypes hinder the understanding of tumor development mechanisms and negatively influence clinical outcomes and treatment approaches. Although some STSs (similar to 20%) have identifiable genetic markers, as specific mutations or translocations, most are characterized by complex genomic profiles. Thus, identification of new therapeutic targets and development of personalized therapies are urgent clinical needs. Although cell lines are useful for preclinical investigations, more reliable preclinical models are required to develop and test new potential therapies. Here, we provide an overview of the available in vitro and in vivo models of visceral sarcomas, whose gene signatures are still not well characterized, to highlight current challenges and provide insights for future studies.
引用
收藏
页数:14
相关论文
共 101 条
  • [1] Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor
    Bauer, Sebastian
    Yu, Lynn K.
    Demetri, George D.
    Fletcher, Jonathan A.
    [J]. CANCER RESEARCH, 2006, 66 (18) : 9153 - 9161
  • [2] A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST
    Blay, Jean-Yves
    [J]. CANCER TREATMENT REVIEWS, 2011, 37 (05) : 373 - 384
  • [3] Managing sarcoma: where have we come from and where are we going?
    Bleloch, Jenna S.
    Ballim, Reyna D.
    Kimani, Serah
    Parkes, Jeannette
    Panieri, Eugenio
    Willmer, Tarryn
    Prince, Sharon
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (10) : 637 - 659
  • [4] Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment
    Braas, Daniel
    Ahler, Ethan
    Tam, Brenna
    Nathanson, David
    Riedinger, Mirielle
    Benz, Matthias R.
    Smith, Kathleen B.
    Eilber, Fritz C.
    Witte, Owen N.
    Tap, William D.
    Wu, Hong
    Christofk, Heather R.
    [J]. CANCER DISCOVERY, 2012, 2 (12) : 1109 - 1117
  • [5] ZIC1 Overexpression Is Oncogenic in Liposarcoma
    Brill, Elliott
    Gobble, Ryan
    Angeles, Christina
    Lagos-Quintana, Mariana
    Crago, Aimee
    Laxa, Bernadette
    DeCarolis, Penelope
    Zhang, Lei
    Antonescu, Cristina
    Socci, Nicholas D.
    Taylor, Barry S.
    Sander, Chris
    Koff, Andrew
    Singer, Samuel
    [J]. CANCER RESEARCH, 2010, 70 (17) : 6891 - 6901
  • [6] Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas
    Brodin, Bertha A.
    Wennerberg, Krister
    Lidbrink, Elisabet
    Brosjo, Otte
    Potdar, Swapnil
    Wilson, Jennifer N.
    Ma, Limin
    Moens, Lotte N.
    Hesla, Asle
    Porovic, Edvin
    Bernhardsson, Edvin
    Papakonstantinou, Antroula
    Bauer, Henrik
    Tsagkozis, Panagiotis
    von Sivers, Karin
    Wejde, Johan
    Ostling, Paivi
    Kallioniemi, Olli
    Stragliotto, Christina Linder
    [J]. BRITISH JOURNAL OF CANCER, 2019, 120 (04) : 435 - 443
  • [7] Zebrafish xenograft models of cancer and metastasis for drug discovery
    Brown, Hannah K.
    Schiavone, Kristina
    Tazzyman, Simon
    Heymann, Dominique
    Chico, Timothy J. A.
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2017, 12 (04) : 379 - 389
  • [8] A Trp53 fl/fl Pten fl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging
    Buchakjian, Marisa R.
    Merritt, Nicole M.
    Moose, Devon L.
    Dupuy, Adam J.
    Tanas, Munir R.
    Henry, Michael D.
    [J]. PLOS ONE, 2017, 12 (08):
  • [9] Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Casali, P. G.
    Blay, J. Y.
    Abecassis, N.
    Bajpai, J.
    Bauer, S.
    Biagini, R.
    Bielack, S.
    Bonvalot, S.
    Boukovinas, I
    Bovee, J. V. M. G.
    Boye, K.
    Brodowicz, T.
    Buonadonna, A.
    De Alava, E.
    Dei Tos, A. P.
    Del Muro, X. G.
    Dufresne, A.
    Eriksson, M.
    Fedenko, A.
    Ferraresi, V
    Ferrari, A.
    Frezza, A. M.
    Gasperoni, S.
    Gelderblom, H.
    Gouin, F.
    Grignani, G.
    Haas, R.
    Hassan, A. B.
    Hindi, N.
    Hohenberger, P.
    Joensuu, H.
    Jones, R. L.
    Jungels, C.
    Jutte, P.
    Kasper, B.
    Kawai, A.
    Kopeckova, K.
    Krakorova, D. A.
    Le Cesne, A.
    Le Grange, F.
    Legius, E.
    Leithner, A.
    Lopez-Pousa, A.
    Martin-Broto, J.
    Merimsky, O.
    Messiou, C.
    Miah, A. B.
    Mir, O.
    Montemurro, M.
    Morosi, C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (01) : 20 - 33
  • [10] The role of novel fusion genes in human GIST cell lines derived from imatinib-resistant GIST patients: A therapeutic potential of fusion gene
    Cho, Woo-Cheol
    Shin, Young-Kyoung
    Na, Young-Soon
    Ryu, Min-Hee
    Ku, Ja-Lok
    Kang, Yoon-Koo
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 529 (03) : 699 - 706